Inspirna, Inc.

Rgenix, Inc.

Isabel Kurth

Masoud Tavazoie

Ivo Lorenz

Foster Casimir Gonsalves

David M Darst, Jr

Shugaku Takeda

Celia Andreu-Agullo

Sohail Tavazoie

Eduardo J Martinez

Bernd Kaiser

Sohail F Tavazoie

Masoud Fakhr Tavazoie

The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g., human MERTK), and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.

High-affinity anti-MERTK antibodies and uses thereof

The invention features methods of treating cancer with β-GPA. The disclosure also provides methods of treating cancer including combinations of β-GPA and additional anti-cancer therapies.

Methods of treating cancer

This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.

LXR agonists and uses thereof

Growing community of inventors

New York, NY, United States of America

Isabel Kurth